RecruitingNCT06195150

Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer


Sponsor

IRCCS San Raffaele

Enrollment

3 participants

Start Date

Nov 8, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this study is to comprehensively map intra and inter tumor heterogeneity of ccRCC in VHL patients through the use of imaging, molecular biology and genomics techniques.


Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This study looks at how kidney tumors in people with Von Hippel-Lindau (VHL) syndrome differ from one another — both within a single tumor and between different tumors in the same person. VHL is a rare inherited condition that causes tumors to grow in the kidneys and other organs. **You may be eligible if...** - You have been diagnosed with VHL syndrome - You have at least 3 kidney tumors larger than 3 cm that need to be surgically removed **You may NOT be eligible if...** - You do not have VHL syndrome - You have fewer than 3 kidney tumors - You are not scheduled for kidney surgery Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood collection

15ml of blood are harvested before surgery


Locations(1)

IRCCS Ospedale San Raffaele

Milan, MI, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06195150


Related Trials